Home > Boards > US Listed > Real Estate > Bluth Company (BLU)

LAVAL, Quebec—April 13, 2021— BELLUS Health Inc. (Nasdaq:BLU;

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
I-Man Member Profile
 
Followed By 68
Posts 8,397
Boards Moderated 0
Alias Born 12/05/07
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/10/2021 4:49:07 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/10/2021 4:31:10 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/10/2021 7:04:04 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/13/2021 7:00:54 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/8/2021 10:17:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/5/2021 11:44:01 AM
Annual Report (foreign Private Issuer) (40-f) Edgar (US Regulatory) - 2/25/2021 5:01:11 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/25/2021 4:03:49 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/22/2021 7:00:57 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 3:16:25 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 7:33:37 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 6:38:24 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 9:38:09 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 6:04:19 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/8/2021 10:18:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 7:01:35 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/28/2020 6:51:34 AM
Voluntary Supplemental Material Filed Pursuant to Section 11(a) of the Securities Act of 1933 by Foreign Issuers (suppl) Edgar (US Regulatory) - 12/23/2020 5:02:31 PM
Amended Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10/a) Edgar (US Regulatory) - 12/23/2020 4:07:28 PM
Appointment of Agent for Service of Process and Undertaking (f-x) Edgar (US Regulatory) - 12/14/2020 4:41:09 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/14/2020 7:01:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/8/2020 7:01:26 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2020 7:02:11 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 4:10:48 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 7:02:19 AM
I-Man   Tuesday, 04/13/21 07:35:12 AM
Re: richrichrich post# 445
Post # of 452 

LAVAL, Quebec—April 13, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.

Presentation Details:

Event: Bloom Burton & Co. Healthcare Investor Conference
Date/Time: Tuesday, April 20, 2021 at 2:00 p.m. ET

A live webcast of the presentation may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.

Chronic pruritus associated with atopic dermatitis is an irritating sensation that leads to scratching and persists for longer than 6 weeks in atopic dermatitis patients. It is estimated that 5% of adults in the United States suffer from atopic dermatitis – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting atopic dermatitis, there continues to be a lack of options targeting the burden of pruritus in patients with atopic dermatitis.


FOR MORE INFORMATION, PLEASE CONTACT:
Danny Matthews
Director, Investor Relations and Communications
danny@bellushealth.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences